High Hepatitis C Prevalence in Medium-Term Residential Addiction Treatment Centers in Kurdistan Province, Iran, 2018

Abdorrahim Afkhamzadeh 1, Farnaz Zandvakili 2, Khaled Rahmani 3,* and Afshin Bahmani 1

1Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
2Department of Obstetrics and Gynecology, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
3Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
*Corresponding author: Assistant Professor of Epidemiology, Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, IR Iran. Email: khaledrahmani111@yahoo.com

Received 2019 January 30; Revised 2019 June 16; Accepted 2019 September 02.

Abstract

Background: Using medium-term residential addiction treatment centers or camps is a routine intervention in Iran.
Objectives: The present study aimed at evaluating the seroprevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) infections among addicts kept in drug addiction camps in Kurdistan province of Iran.
Patients and Methods: The current cross sectional study was conducted on 444 drug abusers engaged in the recovery process residing in 12 rehabilitation camps in Kurdistan province, Iran in 2018. The potential risk factors were collected through a checklist and assessed mainly via a standard validated questionnaire. Participants were also tested for anti-HCV, HBsAg (hepatitis B virus surface antigen), and anti-HIV IgG. Data were analyzed by descriptive methods and logistic regression model in SPSS version 21.
Results: Totally, 444 drug abusers, 98.4% male and 1.6% female, included in the study, out of which 64 (14.4%) subjects had HCV infection and two (0.4%) had coinfection with HBV and HIV based on the results of the enzyme-linked immunosorbent assay (ELISA). Higher age, single marital status, history of drug injection, and tattooing were significant factors related to HCV infection.
Conclusions: The obtained results demonstrated that seroprevalence of HCV among addicts engaged in the recovery process in rehabilitation camps was high. High prevalence of HCV and risk of infection transmission to other addicts in camps should be considered as one of the concerns of the health system in Iran.

Keywords: Hepatitis C, Addiction, Substance-Related Disorders, Health Facility Closure (Camps)

1. Background

Addiction is one of the most important problems throughout the world caused by various social, psychological, and biological factors (1). According to World Health Organization (WHO) reports, it is estimated that 230 million people worldwide have a substance abuse problem (2). Due to proximity to Afghanistan, Iran is a target country for substance dealers and recent studies show increasing prevalence of drug abuse in Iran (3, 4). Based on a network scale-up study, the most common types of drugs used in Iran are opium, opium dross (shireh), and crystal methamphetamine (5). Officials in Iran are always seeking solutions to control addiction in the community. Establishment of medium-term residential addiction treatment centers (camps), narcotics anonymous (NA), and methadone maintenance therapy centers, publicly and privately, are three main interventional programs or approaches to cope with addiction in Iran.

Based on the report of Iran’s Deputy Drug Control Headquarters, by the end of 2016 more than 5233 authorized camps are dedicated to addiction treatment and harm reduction operationally in Iran (6). Camps are important centers to treat addicted individuals and tend to operate in both residential areas and the medium-term (30 - 90 days). The main approach of these camps is to focus on collaboration of peer and self-help groups and their services are usually offered by recovered individuals (7). Although the main goal of these centers is recovery of addicts, there is no strong evidence about their success. Additionally, the gathering of high-risk individuals at the camps has the risk of transmitting some infectious diseases among drug users that are always at risk of developing blood-borne viruses including viral hepatitis B, C, and HIV due to their potential high-risk behaviors and other hazards that threaten them (6). It should be noted that little attention is paid to the service quality provided at substance abuse treatment camps and their role in assisting drug addiction recovery.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Based on the opinion of General Director of Drug Abuse Prevention and Treatment Office, Iran’s Welfare Organization, little attention is paid to the quality of services provided at camps and their role in assisting the recovery of people attending such centers; in contrary, the camps officials claim to implement abstinence-based treatments (7). In addition to the need for further evidence about effectiveness of camps as an approach to treat drug abuse, a camp is one of the most important cumulative sites that can contribute to the transmission of infectious diseases, especially the ones transmitted through blood and secretions. Additionally, addicts referring to these camps are at high risk for HIV and hepatitis B and C infections. Based on the available scientific evidence, high-risk behaviors that cause transmission of blood-borne and sexually transmitted diseases are more common in addicts than in the general population (8, 9). Despite the mentioned facts, camps are still essential to treat addiction in Iran and the systematic surveillance of major communicable diseases in these centers seems to be essential and can help health officials to evaluate preventive measures used to control communicable diseases and design related interventions. To the authors’ best knowledge, there is no sufficient evidence regarding the prevalence of blood-borne diseases in camps in Iran.

2. Objectives

The present study aimed at evaluating the seroprevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) infections in residents of camps in Kurdistan province, Northwest of Iran.

3. Patients and Methods

3.1. Study Design, Setting, Study Subjects and Data Collection

The current cross-sectional study was conducted on addicts kept in rehabilitation camps in Kurdistan province, Northwest of Iran in 2018. The study data were gathered in two consecutive steps. First, demographic data and required information about history of risky behaviors in the study participants were gathered through a face-to-face questionnaire-based interview. The employed questionnaire to obtain risky behaviors was a form of behavioral surveillance surveys (BSS) validated (10) and used in a national study (11). Interview and pretest counselling was performed in a private room on each site. A trained interviewer used a structured questionnaire to gather the data on sociodemographic characteristics and main variables related to HCV, HBV, and HIV such as substance abuse, risky sexual behaviors, the number of partners, condom use, tattooing, history of surgery, and imprisonment. In the second step, a serum sample was used to determine the status of the participants in terms of HCV, HBV, and HIV infections. All experiments were conducted in a central laboratory located in Counseling Center for Behavioral Diseases in the center of province, Sanandaj.

3.2. Laboratory Tests for HBsAg, HCV and HIV Antibodies

The blood samples of study subjects were used to determine the seroprevalence of investigated infections. All tests were performed in accredited reference laboratories on collected blood samples by venous puncture. Serum samples were tested for hepatitis B surface antigen (HBsAg) through the enzyme-linked immunosorbent assay (ELISA) technique, using Hepanostika HBsAg (Murex Biotech Ltd, Dartford, the UK). Similarly, anti-HCV IgG was detected using ELISA technique (Murex anti-HCV version 4.0). Each subject’s serum sample was also screened for HIV-1 and HIV-2 using Vironostika HIV Uni-Form II Ag/Ab (BioMerieux, Boxtel, the Netherlands). All tests were performed following the manufacturer’s instructions.

3.3. Data Analysis

In order to minimize the error in data entry, after completion and collection of questionnaires at each camp, data were transferred to the statistical software by a trained person. In cases of deficiencies in completing the questionnaires, defective items were corrected by telephone follow-up from the site of the sampling. The researchers received the test results from the laboratory at the Counseling Center for Behavioral Diseases in the province in accordance with the questionnaires. The results of the experiments were attached to the questionnaires according to the specified codes. After attaching these laboratory results, determining the status of HCV, HBV, and HIV infections in each subject, final information for all participants was provided. Then data were entered into STATA software version 13 and analyzed. In the data analysis, in addition to using the descriptive methods to summarize the demographic and independent variables, the prevalence of each of the investigated infections was calculated. In addition to univariate analysis and calculation of unadjusted odds ratio (OR), logistic regression model was employed to determine possible risk factors associated with HCV infection as the main dependent variable in the current study, after controlling potential confounders. An alpha of 0.05 was used as the cutoff point for significance, and P values lower than 0.05 were considered statistically significant in all analytical analyses.
3.4. Ethical Consideration

The study protocol was reviewed and approved by the Research Ethics Committee of Kurdistan University of Medical sciences (code No. IR.MUK.REC.1396.352). Before collecting the required data and taking the blood samples, the interviewer introduced the study objectives, and a written informed consent was obtained from each participant. Studied subjects were also assured that all information would remain confidential. They were informed that their participation was voluntary and that participants were also free to discontinue the study at any time.

4. Results

A total of 444 participants, 437 males and seven females, in 12 camps were investigated. Mean and standard deviation of age of the studied participants was 33.50 ± 7.98 years, ranging 18 - 59. Demographic characteristics and history of drug abuse and other risky behaviors in the studied participants are detailed in Table 1.

Of the 444 studied subjects, 64 individuals were positive for HCV infection. Two subjects were positive for HBV infection, and two were also positive for HIV infection. In other words, the prevalence of HCV, HBV, and HIV infections in the studied participants was 14.4% (95% confidence interval (CI): 14.1 - 18.1), 0.04% (95% CI: 0.01 - 0.17), and 0.04% (95% CI: 0.01-0.17), respectively. Table 2 shows the total number of screened and positive cases (prevalence) for HCV, HBV, and HIV infections in each camp.

Since the prevalence of HBV- and HIV-positive cases in the studied participants was very low, in the statistical analysis, the relationship between the independent variables with the prevalence of HBV and HIV infections was not modeled, but logistic regression model was used to assess the relationship between studied independent factors and HCV infection. The results of logistic regression modeling including values of OR, 95% CI for OR, and P value are shown in Table 3.

As shown in Table 3, after controlling other variables, the most important variable associated with HCV infection was the history of drug injection; therefore, the risk of having a HCV infection in subjects with a history of drug injection was 22.97 times higher than those of other individuals (P < 0.001). The age difference of the subjects was also significant; therefore, with one year increase in age, the chance for HCV infection significantly increased by 1.14 times (P < 0.001). Also, the risk of HCV infection in single participants and the ones with a history of imprisonment was 3.13 and 2.77 times higher, respectively (P < 0.05).

5. Discussion

The current study investigated the seroprevalence of HCV, HBV, and HIV infections among addicts attending the camps, centers for addiction treatment, in Kurdistan province, Iran. According to the obtained results, the
prevalence of HBV and HIV infections was low, whereas the frequency of HCV infection was high in the subjects. Based on the existing evidence, the prevalence of HCV in Iran can be highly correlated with drug injection, especially injecting drug users (IDUs) with a history of syringe or needle sharing; in a study by Zamani et al., conducted on IDUs in Tehran, prevalence of HCV infection was reported 52.0% (12). It should be noted that most addicts assessed in the current study (79.3%) had no history of drug injection, while the prevalence of HCV in IDUs (n = 92) assessed in the current study was 56.5%; higher than previous studies. Additionally, the two HBV-positive cases and one of the two HIV-positive cases were IDU. The current study result was consistent with global estimates of HCV prevalence among IDUs (minimum 50%) (13).

According to the two review studies in Iran, prevalence of HCV infection in general population is estimated less than 1.7% (ranging from 0.08% to 1.6%) (14, 15). In addition to the HCV, the residents of the studied camps were also screened for HBV and HIV infections. Based on the obtained results, prevalence of these two infections was low; therefore, two cases were found positive for HBV and two cases had HIV infection. It seems that lower prevalence of HBV in Iran can be attributed to the widespread use of HBV vaccine in infants, children, and high risk groups such as healthcare workers, prisoners, barbers, and patients with thalassemia and hemophilia, and also the ones undergoing hemodialysis (16, 17). Lower prevalence of HIV infection can also be attributed to the spread of harm reduction programs including the distribution of free syringes and needles among addicts, as well as low prevalence of HIV in the general population (11, 18, 19).

Although, the prevalence of HCV among general population of Iran was low in comparison with other developing countries due to strict plan for HCV infection screening prior to any blood transfusion, which started at national level in 1996 (20), prevalence of HCV infection among some vulnerable groups such as IDUs and prisoners is higher than general population. Based on the current study data, in addition to the role of injecting drug and needle sharing as the main risk factor for HCV infection, history of imprisonment was a predicting factor; therefore, the chance of HCV infection in individuals with a history of imprisonment was 7.62 (3.53 - 16.41) times higher than the others.

The other significant risk factor for HCV infection in the current study was advanced age. It should be noted that more diagnosed cases with HCV and HIV infection in Iran can be attributed to previous outbreaks in IDUs during the years of 1998 - 2005 and before conducting widespread harm reduction programs; therefore, it can be concluded that during recent years and following implementation of nationwide harm reduction programs, the rate of transmission of HCV and HIV infections among vulnerable groups such as IDUs reduced (21, 22).

In general, the most important causative factor for HCV in Iran was needle sharing among IDUs and this vulnerable group was one of the main groups attending the camps. The large number of drug addiction camps in Iran and the risk of transmission of HCV and HIV among addicts residing in them is one of the main ongoing concerns of health
Table 3. Logistic Regression to Assess the Relationship Between the Studied Factors and HCV Infection

| Variable                  | Unadjusted OR (95% CI)* | P Value | Adjusted OR (95% CI)* | P Value |
|---------------------------|-------------------------|---------|------------------------|---------|
| Age, y                    | 1.09 (1.05 - 1.12)      | < 0.001 | 1.14 (1.07 - 1.20)     | < 0.001 |
| Age of onset of drug use  | 0.90 (0.84 - 0.96)      | 0.001   | 0.95 (0.86 - 1.04)     | 0.3     |
| Gender                    |                         |         |                        |         |
| Female                    | 1                       | -       | -                      | -       |
| Male                      | 1.01 (0.12 - 8.54)      | 0.9     | -                      | -       |
| Education                 |                         |         |                        |         |
| Illiterate                | 1                       | -       | -                      | -       |
| Under diploma             | 2.27 (0.41 - 12.55)     | 0.3     | -                      | -       |
| Diploma                   | 2.12 (0.62 - 7.21)      | 0.2     | -                      | -       |
| Academic                  | 1.65 (0.45 - 6.10)      | 0.4     | -                      | -       |
| Marital status            |                         |         |                        |         |
| Married                   | 1                       | -       | 1                      | -       |
| Single                    | 3.98 (1.91 - 8.30)      | < 0.001 | 3.13 (1.36 - 8.47)     | 0.02    |
| IDU                       |                         |         |                        |         |
| No                        | 1                       | -       | 1                      | -       |
| Yes                       | 36.83 (18.14 - 74.77)   | < 0.001 | 22.97 (10.01 - 52.71)  | < 0.001 |
| Prior camp use            |                         |         |                        |         |
| No                        | 1                       | -       | 1                      | -       |
| Yes                       | 3.99 (1.91 - 8.30)      | < 0.001 | 1.84 (0.67 - 5.10)     | 0.2     |
| History of prisoning      |                         |         |                        |         |
| No                        | 1                       | -       | 1                      | -       |
| Yes                       | 7.62 (3.53 - 16.41)     | < 0.001 | 2.77 (1.03 - 7.45)     | 0.04    |
| History of tattooing      |                         |         |                        |         |
| No                        | 1                       | -       | 1                      | -       |
| Yes                       | 4.29 (2.17 - 8.47)      | < 0.001 | 1.79 (0.73 - 4.39)     | 0.2     |
| History of surgery        |                         |         |                        |         |
| No                        | 1                       | -       | 1                      | -       |
| Yes                       | 1.35 (0.79 - 2.30)      | 0.3     | -                      | -       |
| Heterosexual risky behavior|                         |         |                        |         |
| No                        | 1                       | -       | 1                      | -       |
| Yes                       | 1.67 (0.97 - 2.87)      | 0.06    | 0.86 (0.37 - 2.04)     | 0.7     |

Abbreviation: IDU, injecting drug user.

officials and policy makers. The implementation of preventive measures and sufficient supervision on the activities of these camps and conducting studies to assess the effectiveness of such camps in Iran is an undeniable necessity.

To the authors’ best knowledge, it was the first project that assessed the prevalence of main blood-borne infections (HCV, HBV, and HIV) in camps, the medium-term residential addiction treatment centers in Iran. Since all residents of the camps were examined at the same time, there was no specific limitation in terms of methodology in the study.

Acknowledgments

This project was financially supported by the Vice Chancellor for Research of Kurdistan University of Medical
Science (IR.MUK.REC.1396.352). Authors gratefully thank the personnel of Vice Chancellor for research of Kurdistan University of Medical Sciences and managers of all studied camps.

Footnotes

Authors’ Contribution: Study concept and design: Khaled Rahmani and Abdorrahim Afkhamzadeh; acquisition of data: Khaled Rahmani and Afshin Bahmani; analysis and interpretation of data: Khaled Rahmani and Afshin Bahmani; drafting of the manuscript: Khaled Rahmani and Farnaz Zandvakil; critical revision of the manuscript for important intellectual content: Khaled Rahmani and Farnaz Zandvakil; statistical analysis: Khaled Rahmani and Afshin Bahmani; administrative, technical, and material support: Farnaz Zandvakil and Abdorrahim Afkhamzadeh; study supervision: Abdorrahim Afkhamzadeh.

Conflict of Interests: All the authors declared no conflict of interest.

Ethical Approval: The project protocol was confirmed by the Ethical Committee of Kurdistan University of Medical Sciences (code No. IR.MUK.REC.1396.352).

Funding/Support: This project was financially supported by the Vice Chancellor for research of Kurdistan university of medical sciences (IR.MUK.REC.1396.352).

References

1. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: Results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320–33. doi: 10.1111/add.12551. [PubMed: 24662727].
2. Fedotov Y. World drug report 2012. UNODC United Nations Publication Sales; 2014.
3. Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajeji A, Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit drug use disorders in Iran: Prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction. 2016;111(10):1836–47. doi: 10.1111/add.13453. [PubMed: 27778449].
4. Tayebani T, Sohrabi A, Samouei R. The job burnout of therapists in the licensed addiction centers in Isfahan, Iran and its relationship with individual and professional factors. Dir Gen. 2013;9(7):3015–23. Persian.
5. Nikfarjam A, Shokoohi M, Shahesmaei A, Haghdoot AA, Baneshi MR, Haj-Maghsoodi S, et al. National population size estimation of illicit drug users through the network scale-up method in 2013 in Iran. Int J Drug Policy. 2016;31:147–52. doi: 10.1016/j.drugpo.2016.01.013. [PubMed: 26980349].
6. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e192–207. doi: 10.1016/S2214-409X(17)30375-3. [PubMed: 29074409]. [PubMed Central: PMC5683758].
7. Shamsalnia A, Nourozi K, Khoshnakb MF, Farhoudian A. Challenges of recovery in medium-term residential centers (camps). Med J Islam Repub Iran. 2014;28:106. [PubMed: 25664307]. [PubMed Central: PMC4301226].
8. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):148–76. doi: 10.1016/S2468-1253(16)30181-9. [PubMed: 28404132].
9. Maclachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5). a018410. doi: 10.1101/cshperspect.a018410. [PubMed: 25934461]. [PubMed Central: PMC4448582].
10. Amon J, Brown T, Hogle J, MacNeil J, Magnani R, Mills S. Behavioral surveillance surveys BSS. Guidelines for repeated behavioral surveys in populations at risk of HIV. 2000.
11. Navadeh S, Mirzaezadeh A, Gouya MM, Farnia M, Alavand R, Haghdoot AA. HIV prevalence and related risk behaviours among prisoners in Iran: Results of the national biobehavioural survey, 2009. Sex Transm Infect. 2011;87 Suppl 3:i33–6. doi: 10.1136/sextrans-2011-051205. [PubMed: 23986417]. [PubMed Central: PMC3841726].
12. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2017;55:539–63. doi: 10.1016/j.drugpo.2017.02.007. [PubMed: 27854723].
13. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352–8. doi: 10.1016/j.drugpo.2007.04.004. [PubMed: 27854722].
14. Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH, et al. Update on the prevalence of hepatitis C virus infection among Iranian general population: A systematic review and meta-analysis. Hepat Mon. 2017;17(2):e42291. doi: 10.5812/hepatmon.42291.
15. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005;8(2):34–90.
16. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):359–63. doi: 10.18193/ijgdl.2007.04.013. [PubMed: 17893122].
17. Salehi-Vaziri M, Sadeghi F, Almasi Hashimani A, Golami Fesharaki M, Alavian SM. Hepatitis B virus infection in the general population of Iran: An updated systematic review and meta-analysis. Hepat Mon. 2016;16(4). e35577. doi: 10.5812/hepatmon.35577. [PubMed: 27257428]. [PubMed Central: PMC4888501].
18. Himmich H, Madani N. The state of harm reduction in the Middle East and North Africa: A focus on Iran and Morocco. Int J Drug Policy. 2016;31:184–9. doi: 10.1016/j.drugpo.2016.02.013. [PubMed: 27092581].
19. Rahnama R, Mohraz M, Mirzaezadeh A, Rutherford G, McFarland W, Akbari G, et al. Access to harm reduction programs among persons who inject drugs: Findings from a respondent-driven sampling survey in Tehran, Iran. Int J Drug Policy. 2014;25(4):717–23. doi: 10.1016/j.drugpo.2014.05.005. [PubMed: 24974367]. [PubMed Central: PMC421781].
20. Rezvan H, Abolghassemi H, Kafabadi SA. Transfusion-transmitted infections among multitransfused patients in Iran: A review. Transfus Med. 2007;17(6):425–33. doi: 10.1111/j.1365-3148.2007.00794.x. [PubMed: 18067646].
21. Shahbazi M, Farnia M, Rahmani K, Moradi G. Trend of HIV/AIDS prevalence in Iran: An updated systematic review and meta-analysis. Dir Gen. 2016;10(4):1836–47. doi: 10.1111/add.13453. [PubMed: 27257428]. [PubMed Central: PMC4448582].
22. Nissaramanesh B, Trace M, Roberts M. The rise of harm reduction in the Islamic Republic of Iran. Beckley Foundation Drug Policy Programme, Briefing Paper; 2005.